dasotraline 4mg

DRUG2 trials

Sponsors

Sumitomo Pharma America, Inc.

Conditions

Attention-Deficit Hyperactivity Disorder (ADHD)Binge Eating Disorder

Phase 3

A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

CompletedNCT02734693

Sumitomo Pharma America, Inc.Attention-Deficit Hyperactivity Disorder (ADHD)

Start: 2016-04-30End: 2017-02-28Updated: 2020-03-27

A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder

CompletedNCT03107026

Sumitomo Pharma America, Inc.Binge Eating Disorder

Start: 2017-03-31End: 2018-05-16Updated: 2020-07-13

Related Papers

Characterization of the Safety Profile of the Triple Monoamine Reuptake Inhibitor Dasotraline Based on Clinical Trial Data and Disproportionality Analyses of Four Related Pharmacological Classes Using Real-World Data from the FDA Adverse Event Reporting System.

2026-02-16

170 Efficacy and Safety of Dasotraline in Adults with Binge-Eating Disorder: A Randomized, Double-blind, Fixed-dose Trial

CNS Spectrums2020-04-013 citations

180 Efficacy of Dasotraline in Children With Attention Deficit Hyperactivity Disorder in a Laboratory Classroom Setting

CNS Spectrums2018-02-011 citations